New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
18:05 EDTZTSZoetis could climb 25%, Barron's says
Zoetis (ZTS) isn't subject to the same patent expiration cliff as Pfizer (PFE) and earnings should rise 13% over the next few years, Barron's says in its "Weekday Trader" column. Shares could climb 25%, the paper adds. Reference Link
News For ZTS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
11:57 EDTZTSAckman set to win two seats on Zoetis board, Reuters says
Subscribe for More Information
11:44 EDTZTSAckman set to win seats on Zoetis board, Reuters reports
January 15, 2015
09:20 EDTZTSZoetis could be worth about $90 per share, says Guggenheim
Guggenheim believes that Zoetis' ability to sustain double-digit earnings growth for the foreseeable future is not yet fully reflected in its stock price. The firm says the company's EPS could rise to $3-$4 by 2018, versus the consensus outlook of $2.43. Guggenheim identifies the stock as its best idea and keeps a Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use